Bays H - Search Results

1

JCL roundtable: Clinical management of individuals with obesity.

Brown WV, Bays H, Bray GA. Brown WV, et al. Among authors: bays h. J Clin Lipidol. 2014 May-Jun;8(3):237-48. doi: 10.1016/j.jacl.2014.02.005. Epub 2014 Feb 15. J Clin Lipidol. 2014. PMID: 24793344

2

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.

Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E; Rosuvastatin Study Group. Brown WV, et al. Among authors: bays he. Am Heart J. 2002 Dec;144(6):1036-43. doi: 10.1067/mhj.2002.129312. Am Heart J. 2002. PMID: 12486428 Clinical Trial.

3

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Erondu N, et al. Among authors: bays h. Cell Metab. 2006 Oct;4(4):275-82. doi: 10.1016/j.cmet.2006.08.002. Cell Metab. 2006. PMID: 17011500 Free article. Clinical Trial.

4

Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.

Erondu N, Wadden T, Gantz I, Musser B, Nguyen AM, Bays H, Bray G, O'Neil PM, Basdevant A, Kaufman KD, Heymsfield SB, Amatruda JM. Erondu N, et al. Among authors: bays h. Obesity (Silver Spring). 2007 Apr;15(4):895-905. doi: 10.1038/oby.2007.620. Obesity (Silver Spring). 2007. PMID: 17426325 Free article. Clinical Trial.

5

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.

Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Bays HE, et al. Expert Rev Cardiovasc Ther. 2008 Mar;6(3):343-68. doi: 10.1586/14779072.6.3.343. Expert Rev Cardiovasc Ther. 2008. PMID: 18327995 Review.

6

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.

Bays HE, Shah A, Lin J, McCrary Sisk C, Paolini JF, Maccubbin D. Bays HE, et al. J Clin Lipidol. 2010 Nov-Dec;4(6):515-21. doi: 10.1016/j.jacl.2010.08.020. Epub 2010 Oct 28. J Clin Lipidol. 2010. PMID: 21122699 Clinical Trial.

7

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.

Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, Buttler SM, Sleep DJ, Stolzenbach JC. Bays HE, et al. J Clin Lipidol. 2008 Dec;2(6):426-35. doi: 10.1016/j.jacl.2008.10.001. Epub 2008 Nov 12. J Clin Lipidol. 2008. PMID: 21291776

8

Drugs in development for management of lipoprotein disorders.

Brown WV, Bays H, Davidson M, Goldberg A. Brown WV, et al. Among authors: bays h. J Clin Lipidol. 2011 Mar-Apr;5(2):66-75. doi: 10.1016/j.jacl.2011.01.004. Epub 2011 Jan 28. J Clin Lipidol. 2011. PMID: 21392719 No abstract available.

9

Using omega-3 fatty acids in the practice of clinical lipidology.

Brown WV, Bays H, Harris W, Miller M. Brown WV, et al. Among authors: bays h. J Clin Lipidol. 2011 Nov-Dec;5(6):424-33. doi: 10.1016/j.jacl.2011.09.006. Epub 2011 Oct 2. J Clin Lipidol. 2011. PMID: 22108145 No abstract available.

10

Planning a clinical trial.

Brown WV, Bays HE, Maki KC, Wild RA. Brown WV, et al. J Clin Lipidol. 2012 Nov-Dec;6(6):484-95. doi: 10.1016/j.jacl.2012.10.001. Epub 2012 Oct 5. J Clin Lipidol. 2012. PMID: 23312046 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

343 results

Search Page